Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 568

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia

Open access
Whyte, Michael P., Greenberg, Cheryl R., Salman, Nada J., Bober, Michael B., McAlister, William H., Wenkert, Deborah, Van Sickle, Bradley J., Simmons, Jill H., Edgar, Terence S., Bauer, Martin L., Hamdan, Mohamed A., Bishop, Nick, Lutz, Richard E., McGinn, Mairead, Craig, Stanley, Moore, Jean N., Taylor, John W., Cleveland, Robert H., Cranley, William R., Lim, Ruth, Thacher, Tom D., Mayhew, Jill E., Downs, Matthew, Millán, José Luis, Skrinar, Alison M., Crine, Philippe, Landy, Hal·2012·New England Journal of Medicine

Abstract

BACKGROUND: Hypophosphatasia results from mutations in the gene for the tissue-nonspecific isozyme of alkaline phosphatase (TNSALP). Inorganic pyrophosphate accumulates extracellularly, leading to rickets or osteomalacia. Severely affected babies often die from respiratory insufficiency due to progressive chest deformity or have persistent bone disease. There is no approved medical therapy. ENB-0040 is a bone-targeted, recombinant human TNSALP that prevents the manifestations of hypophosphatasia in Tnsalp knockout mice. METHODS: We enrolled infants and young children with life-threatening or debilitating perinatal or infantile hypophosphatasia in a multinational, open-label study of treatment with ENB-0040. The primary objective was the healing of rickets, as assessed by means of radiographic scales. Motor and cognitive development, respiratory function, and safety were evaluated, as well as the pharmacokinetics and pharmacodynamics of ENB-0040. RESULTS: Of the 11 patients recruited, 10 completed 6 months of therapy; 9 completed 1 year. Healing of rickets at 6 months in 9 patients was accompanied by improvement in developmental milestones and pulmonary function. Elevated plasma levels of the TNSALP substrates inorganic pyrophosphate and pyridoxal 5'-phosphate diminished. Increases in serum parathyroid hormone accompanied skeletal healing, often necessitating dietary calcium supplementation. There was no evidence of hypocalcemia, ectopic calcification, or definite drug-related serious adverse events. Low titers of anti-ENB-0040 antibodies developed in four patients, with no evident clinical, biochemical, or autoimmune abnormalities at 48 weeks of treatment. CONCLUSIONS: ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1106173

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 568

Metadata

Authors
Whyte, M. P., Greenberg, C. R., Salman, N. J., Bober, M. B., McAlister, W. H., Wenkert, D., Van Sickle, B. J., Simmons, J. H., Edgar, T. S., Bauer, M. L., Hamdan, M. A., Bishop, N., Lutz, R. E., McGinn, M., Craig, S., Moore, J. N., Taylor, J. W., Cleveland, R. H., Cranley, W. R., Lim, R., Thacher, T. D., Mayhew, J. E., Downs, M., Millán, J. L., Skrinar, A. M., Crine, P., & Landy, H.
Venue
New England Journal of Medicine
Published
2012-03-08
Volume
366
Issue
10
Pages
904-913
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2141225628
Cited by
568
References
2
FWCI
28.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia. https://app.cochat.ai/papers/10.1056/nejmoa1106173
The paper
Whyte, M. P., Greenberg, C. R., Salman, N. J., Bober, M. B., McAlister, W. H., Wenkert, D., Van Sickle, B. J., Simmons, J. H., Edgar, T. S., Bauer, M. L., Hamdan, M. A., Bishop, N., Lutz, R. E., McGinn, M., Craig, S., Moore, J. N., Taylor, J. W., Cleveland, R. H., Cranley, W. R., . . . Landy, H. (2012). Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1106173

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.